Literature DB >> 24282469

Alpha-fetoprotein and carbohydrate antigen 19-9 producing advanced adenocarcinoma of renal pelvis and ureter.

Kai Yang1, Xiang-Yi Zheng, Yan-Li Wang, Kui Zhao, Hai Jiang.   

Abstract

Tumour markers producing primary adenocarcinoma of upper urinary tract is extremely rare. We report a case of advanced adenocarcinoma of renal pelvis and ureter with highly elevated serum levels of alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-9). This 66-year-old man was diagnosed with left renal pelvic and ureteral tumours with para-aortic lymph node swelling, with no evidence of abnormality in his digestive or reproductive system. He was successfully treated with left nephroureterectomy and lymph node dissection followed by gemcitabine/carboplatin chemotherapy and the serum levels of AFP and CA19-9 decreased to normal. Pathological examination revealed a moderately or poorly differentiated intestinal-type adenocarcinoma with para-aortic lymph node metastasis. The patient was followed up for 11 months after surgery without recurrence.

Entities:  

Year:  2013        PMID: 24282469      PMCID: PMC3840518          DOI: 10.5489/cuaj.1544

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  14 in total

1.  Papillary adenocarcinoma of the ureter producing carcinoembryonic antigen and carbohydrate antigen 19-9.

Authors:  Yoshio Aida; Osamu Kudo; Katsunori Yamakawa; Keiko Kato; Mamoru Tadokoro; Takeshi Takahashi
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450

2.  Successful treatment with paclitaxel/carboplatin chemotherapy in advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.

Authors:  Manabu Kato; Takehisa Onishi; Akira Hoshina; Tadasihi Yabana
Journal:  Urol Int       Date:  2010-02-17       Impact factor: 2.089

3.  Renal pelvic tumors.

Authors:  H Grabstald; W F Whitmore; M R Melamed
Journal:  JAMA       Date:  1971-11-08       Impact factor: 56.272

4.  [Port site metastasis of primary adenocarcinoma of the renal pelvis after a laparoscopic nephrectomy: a case report].

Authors:  Yoshitomo Kobori; Kazuyoshi Shigehara; Toshiyasu Amano; Katsuro Takemae
Journal:  Hinyokika Kiyo       Date:  2005-02

5.  Papillary adenocarcinoma of the renal pelvis and ureter producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.

Authors:  Takehisa Onishi; Omar E Franco; Takuji Shibahara; Kiminobu Arima; Yoshiki Sugimura
Journal:  Int J Urol       Date:  2005-02       Impact factor: 3.369

6.  Hepatoid adenocarcinoma of the renal pelvis producing alpha-fetoprotein of hepatic type and bile pigment.

Authors:  H Ishikura; T Ishiguro; C Enatsu; H Fujii; Y Kakuta; M Kanda; T Yoshiki
Journal:  Cancer       Date:  1991-06-15       Impact factor: 6.860

Review 7.  [A case of transitional cell carcinoma of the renal pelvis with adenocarcinoma producing CEA and CA19-9].

Authors:  Yoh Matsuoka; Hisashi Ishimaru; Gaku Arai; Junko Aida; Yume Okada; Yuji Ito
Journal:  Hinyokika Kiyo       Date:  2004-09

Review 8.  Primary mucinous adenocarcinoma of the renal pelvis with elevated CEA and CA19-9.

Authors:  Yun-Lin Ye; Jun Bian; Yan-Ping Huang; Yan Guo; Zhi-Xun Li; Chun-Hua Deng; Yu-Ping Dai; Xiang-Zhou Sun
Journal:  Urol Int       Date:  2011-09-01       Impact factor: 2.089

9.  Alpha-fetoprotein-producing adenocarcinoma of the ureter.

Authors:  M Hosomi; S Sagawa; Y Kotou
Journal:  Urol Int       Date:  1992       Impact factor: 2.089

10.  CA125-producing clear cell adenocarcinoma arising from the upper ureter and renal pelvis.

Authors:  Chi-Min Shih; Chuan-Te Huang; Ching-Huang Chi; Jui-Wei Lin; Chin-Chen Pan
Journal:  J Chin Med Assoc       Date:  2010-01       Impact factor: 2.743

View more
  1 in total

1.  Intestinal metaplasia of the renal pelvis: A case report and literature review.

Authors:  Weimin Zhou; Kuangbiao Zhong; Jingrong Wang; Yonghong Gu; Lihua Huang; Zhiqiang Jiang; Leye He
Journal:  Oncol Lett       Date:  2014-09-18       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.